Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1889541 | 1.00 | IGF1R (0.54) | IGF1RSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL1890910 | 0.90 | IGF1R (0.52) | IGF1RSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL1894221 | 0.90 | IGF1R (0.52) | IGF1RSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL1885148 | 0.90 | IGF1R (0.52) | IGF1RSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL1888999 | 0.90 | IGF1R (0.52) | IGF1RSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL1889115 | 0.90 | IGF1R (0.52) | IGF1RSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL1889052 | 0.90 | IGF1R (0.52) | IGF1RSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL1884610 | 0.90 | IGF1R (0.52) | IGF1RSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL1885146 | 0.90 | IGF1R (0.52) | IGF1RSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL1887278 | 0.90 | IGF1R (0.52) | IGF1RSMN1; SMN2LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-09-22 | — | — | US | disclosed |
| US-7947686-B2 | Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K3, MAP3K1, MAP3K19 | IGF1R 760/4885SMN1; SMN2 3711/4885LMNA 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.